GLP-1 RA Eligibility in Reproductive-Age U.S. Women.

OBJECTIVE

Use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for diabetes or weight management may affect pregnancy outcomes. We sought to estimate the number of U.S. women of reproductive age eligible for GLP-1 RA therapy.

RESEARCH DESIGN AND

METHODS

Using 2017-2023 nationally representative survey data, we identified nonpregnant U.S. women aged 18-44 years who met trial-based eligibility criteria for diabetes, weight management, or secondary cardiovascular prevention.

RESULTS

Among 3,218 participants, 1,447 were eligible for GLP-1 RAs, representing 24.6 million U.S. women. Among GLP-1 RA-eligible women, mean BMI was 34.8 kg/m2, 8.3% had diabetes, and 1.9% had prior cardiovascular disease. Eligibility was primarily for weight management (24.1 million), followed by diabetes (2.0 million) and cardiovascular prevention (0.34 million).

CONCLUSIONS

Nearly half of U.S. reproductive-age women are eligible for GLP-1 RAs. Given limited pregnancy safety data and rising cardiometabolic burden in reproductive-age women, research is needed to guide counseling and coverage of preconception GLP-1 RA use.

UNLABELLED: Video 1.Video abstract4b256fe6-3f25-4d79-adeb-93b3562c7122docm250040video1.